BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei KZ, Baxter M, Casasola R. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. Melanoma Manag 2019;6:MMT13. [PMID: 31236205 DOI: 10.2217/mmt-2018-0009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gubbi S, Hannah-Shmouni F, Verbalis JG, Koch CA. Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab 2019;33:101371. [PMID: 31866206 DOI: 10.1016/j.beem.2019.101371] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
2 Thomas R, Sebastian B, George T, Majeed NF, Akinola T, Laferriere SL, Braschi-Amirfarzan M. A review of the imaging manifestations of immune check point inhibitor toxicities. Clin Imaging 2020;64:70-9. [PMID: 32334270 DOI: 10.1016/j.clinimag.2020.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Killen C. Welcome to volume 7 of Melanoma Management. Melanoma Manag 2020;7:MMT34. [PMID: 32399172 DOI: 10.2217/mmt-2020-0003] [Reference Citation Analysis]
4 Atkins P, Ur E. Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series. Endocrine Research 2020;45:246-53. [DOI: 10.1080/07435800.2020.1817064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Zhang Q, Huo GW, Zhang HZ, Song Y. Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis. Open Med (Wars) 2020;15:447-56. [PMID: 33313405 DOI: 10.1515/med-2020-0110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Al Ashi SI, Thapa B, Flores M, Ahmed R, Rahim SEG, Amir M, Alomari M, Chadalavada P, Morrison SL, Bena JF, Hercbergs A, Lashin O, Daw H. Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. J Endocr Soc 2021;5:bvab100. [PMID: 34195529 DOI: 10.1210/jendso/bvab100] [Reference Citation Analysis]